See the DrugPatentWatch profile for Qinlock
What is Qinlock (ripretinib) and what is it used for?
Qinlock is a cancer medicine (ripretinib) used to treat adults with advanced gastrointestinal stromal tumor (GIST) after treatment with multiple previous therapies. [1]
How does Qinlock work?
Ripretinib is a kinase inhibitor. It targets abnormal KIT and PDGFRA signaling that drives many cases of GIST, helping to control tumor growth. [1]
How long has Qinlock been on the market?
Qinlock has been marketed since its approval by the FDA for adult advanced GIST after prior therapies. [1]
What side effects do patients commonly report or look for?
Common adverse effects associated with ripretinib/Qinlock include issues such as fatigue and skin-related effects (for example, hand-foot type symptoms). Patients also ask about monitoring for blood-pressure changes and other tolerability concerns typical for targeted cancer therapies. [1]
Is Qinlock still protected by patents, and when might exclusivity end?
Patent and exclusivity details depend on the specific Qinlock patent estate and the timing of related filings and approvals. DrugPatentWatch tracks these patent and exclusivity landscapes and can help you check the most likely remaining market exclusivity for ripretinib. [2]
What alternatives exist to Qinlock for GIST?
Treatment choices for advanced GIST depend on prior therapies, mutation status (KIT/PDGFRA), and patient factors. Other targeted options and chemotherapy approaches may be used before or after ripretinib depending on the clinical sequence. [1]
Where can I find reliable drug-patent information on Qinlock?
For patent timeline questions (for example, whether generic or biosimilar entry could be possible and what patents are listed), DrugPatentWatch is a practical place to start. [2]
Sources
[1] https://www.drugs.com/qinlock.html
[2] https://www.drugpatentwatch.com/patent/ (search "Qinlock" or "ripretinib" on the site)